DMPS: LATEST DATA, THE FDA APPROVAL PROCESS AND CLINICAL TIPS with Dr. Paul Anderson [June 13, 2017 at 5:30pm pt]

1.5 General CEU Approved / The live date for this webinar has passed, the replay is available for members below.


WEBINAR ABSTRACT  DMPS has long been used “off-label” in the US as an IV and occasionally oral chelator.  In the past year, it has stood up to an FDA approval process under the 503(a) compounding act.  It is now pending enactment from the approval granted in 2016.  In this presentation Dr. Anderson will share the FDA approval process and how DMPS was approved as well as updated clinical information regarding IV and oral dosing, safety and efficacy.

SPEAKER BIO   Paul Anderson, N.M.D. is CEO of the Anderson Medical Group which includes Advanced Medical Therapies, a state of the art medical center providing fully compliant IV, Hyperbaric and Mild Hyperthermia therapies. He brings his forty years’ experience in medicine to allow his clinical and educational presence to grow and serve patients and physicians in the best way possible. 

Dr. Anderson is former Chief of IV (intravenous therapy) Services for Bastyr Oncology Research Center and a past Professor at Bastyr University. He has participated in ground breaking integrative oncology research and is author to numerous clinical oncology monographs. 

He completed his medical degree at NUNM and trained at multiple hospital and clinical sites in Portland Oregon.  He began instructing classes at medical schools in the early 1990’s.  Additionally, he is a medical author and speaks in many continuing medical education courses and events. He is extending his medical education mission through the Anderson Medical Group CE site ‘’ a web-based educational platform.

You need to be logged in to see this part of the content. Please Login to access.
This entry was posted in Archived Webinars, Events, Webinars. Bookmark the permalink.